PO.MCB11.01 · 分子与细胞生物学

理解错义与无义:肿瘤细胞劫持突变诱导的抑癌因子错误定位

Making sense of mis-sense and non-sense: Tumor cells hijack mutation-induced mis-localization of tumor suppressors

海报缩略图:理解错义与无义:肿瘤细胞劫持突变诱导的抑癌因子错误定位
编号 616 展板 21 时间 4/19 02:00–05:00 区域 Section 25 主讲 Murali Bashyam, PhD
分会场 Tumor Suppressors
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Murali Dharan Bashyam1, Sanjana Sarkar2, Jimlee Saikia1

1Laboratory of Molecular Oncology, BRIC-Centre for DNA Fingerprinting and Diagnostics (BRIC-CDFD), Hyderabad, India,2BRIC-Centre for DNA fingerprinting and Diagnostics (BRIC-CDFD), Hyderabad, India

摘要 Abstract

中文摘要
SWI/SNF染色质重塑复合物利用ATP水解的能量来滑动或驱逐核小体或组蛋白,从而通过驱动'开放'的染色质结构实现核内进程。哺乳动物SWI/SNF,又称BrG1/Brm相关因子(BAF)复合物,是个体发育和成年生命中主要的染色质重塑因子。目前已表征出三种在生化上不同的BAF复合物,即经典型(cBAF)、多溴型(PBAF)和非经典型(ncBAF)。BAF组分被归类为经典的核内抑癌因子,在癌症中频繁发生失活突变。尽管若干研究评估了BAF亚基的功能,但很少有研究尝试表征在各癌症类型中鉴定出的BAF组分突变的作用。在我们此前的研究中,我们鉴定出早发性直肠癌特异性的截断突变,发生在编码PBAF组分'富含A-T相互作用结构域2'(ARID2)的基因中,该突变去除了其核定位信号(NLS)。基于对癌症突变数据库的分析,这些截断突变在各癌症类型中也被鉴定到。NLS失活的ARID2表现出胞质定位(cARID2),并在结直肠癌、乳腺癌和肺癌细胞系中促进肿瘤发生。在此,我们呈现对ARID2截断突变的详细机制表征,这些突变被推测在性质上具有失活作用,但却表现出致癌功能的获得。我们表明,富含谷氨酰胺的GLN结构域(氨基酸793-1128)对cARID2的致癌功能至关重要。串联亲和纯化质谱在野生型而非cARID2的相互作用组中鉴定出PBAF组分,与预期一致。更重要的是,采用生化方法验证了cARID2(而非野生型ARID2)与AKAP8L之间的一种新相互作用。缺失GLN结构域的cARID2不与AKAP8L相互作用。AKAP8L属于含AKAP95结构域的蛋白家族,该家族蛋白与蛋白激酶A(PKA)相互作用并将其激活,从而导致CREB信号的致癌性激活。此外,cARID2使磷酸化(活性)形式的CREB增加,并使包括ATF3、ATF4和CREM在内的经典CREB靶标的转录水平升高,这些是CREB信号轴激活的指标。AKAP8L本身被证明可在CRC细胞中激活肿瘤发生。目前正在进行RNA测序分析,以确认cARID2对PKA/CREB致癌信号的激活。裸鼠异种移植实验也正在进行中,以确认cARID2的致癌潜力。总体而言,这些发现揭示了ARID2在癌症中具有阴阳两面的抑癌/致癌双重作用,类似于我们此前对ARID2旁系同源物ARID1B的发现。更重要的是,我们的研究揭示了针对表现出胞质ARID2的肿瘤的新治疗选择。
查看英文原文 English abstract
The SWI/SNF chromatin remodeler utilizes energy of ATP hydrolysis to slide or evict nucleosomes or histones, thus enabling nuclear processes by driving an ‘open' chromatin architecture. The mammalian SWI/SNF, also termed the BrG1/Brm associated factor (BAF) complex, is the major chromatin remodeler in ontogeny and adult life. Three biochemically distinct BAF complexes namely canonical (cBAF), polybromo (PBAF), and non-canonical (ncBAF) have been characterized. BAF components, classified as canonical nuclear tumor suppressors, exhibit frequent inactivating mutations in cancers. Though, several studies have evaluated the functioning of BAF subunits, very few have attempted to characterize the role of BAF component mutation identified across cancer types. In our previous studies, we identified early-onset rectal cancer specific truncation mutations in the gene encoding the PBAF component ‘A-T rich interaction domain containing 2' ( ARID2 ), precluding its nucleal localization signal (NLS). These truncations were also identified across cancer types based on analysis of cancer mutation databases. NLS-inactivated ARID2 exhibited cytoplasmic localization (cARID2) and promoted tumorigenesis in colorectal, breast and lung cancer cell lines. Here, we present detailed mechanistic characterization of ARID2 truncations, presumed to be inactivating in nature, but exhibiting a gain of oncogenic function. We show that the glutamine rich GLN domain (amino acids 793-1128) is essential for the oncogenic function of cARID2. Tandem affinity purification mass spectrometry identified PBAF components in the interactome of wild-type but not of cARID2, as expected. More importantly, a novel interaction between cARID2 (but not wild type ARID2) and AKAP8L, validated using biochemical approaches. cARID2 devoid of the GLN domain, did not interact with AKAP8L. AKAP8L belongs to the AKAP95 domain containing family of proteins that interact with and activate protein kinase A (PKA) leading to oncogenic activation of CREB signalling. Further, cARID2 effected an increase in the phosphorylated (active) form of CREB and in transcript levels of canonical CREB targets including ATF3, ATF4, and CREM, indicators of activation of the CREB signalling axis. AKAP8L itself was shown to activate oncogenesis in CRC cells. Analysis of RNA Sequencing is currently underway to confirm the activation of the PKA/CREB oncogenic signalling by cARID2. Nude mice xenograft assays are also underway to confirm the oncogenic potential of cARID2. Overall, the findings reveal a Yin-Yang tumor suppressor/oncogenic role for ARID2 in cancer, similar to our previous discovery for ARID1B, an ARID2 paralogue. More importantly, our study has revealed novel therapeutic options for tumors exhibiting cytoplasmic ARID2.
利益披露 Disclosure
M. D. Bashyam, None.. S. Sarkar, None.. J. Saikia, None.

← 返回 AACR 2026 检索